Expect Buzz About Vowst, a New Oral Fecal Microbiota Product

August 2023

Rx Vowst will be the first ORAL fecal microbiota product that’s FDA-approved for preventing C. diff recurrence in adults.

It comes on the heels of FDA approval of Rebyota...a fecal microbiota enema. Other fecal transplant products are investigational.

Any of these options may seem unappealing, but “transplanting” fecal microbiota can help restore a healthy GI flora.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Cardiology Match Antithrombotics With Type of Prosthetic Heart Valve
Infectious Diseases Expect Buzz About Vowst, a New Oral Fecal Microbiota Product
Geriatrics Stay Updated on the New Beers Criteria Guidelines
Pneumonia Know the Role of Steroids for Community-Acquired Pneumonia
Med Safety Help Ensure Appropriate Use of Stimulants
Testosterone Put CV Risks With Testosterone in Perspective
Opioids Use a Stepwise Approach When Converting Opioids
Crohn's Disease Demystify Meds for Moderate to Severe Crohn’s Disease
NatMed Spotlight Be Prepared With Answers About Milk Thistle